Immunic, Inc.: 5%+ holders

Immunic, Inc. has 32 Schedule 13D or 13G filings on record since 2025-07-31. 13 holders' latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Biotechnology Value Fund L P

The Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. Securities Purchase Agreement On February 12, 2026, the Issuer and certain accredited investors (the "Investors"), including certain of the Reporting Persons, entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Issuer agreed to sell and issue to the Investors in a private placement (the "Offering"), pre-funded warrants (the "2026 Pre-Funded Warrants") to purchase Shares, with each 2026 Pre-Funded Warrant accompanied by a warrant (the "Common Warrants") to purchase (i) a Share or (ii) a 2026 Pre-Funded Warrant, at a purchase price of $0.873120 per 2026 Pre-Funded Warrant and accompanying Common Warrant. The Offering closed (the "Closing") on February 17, 2026 (the "Closing Date"). In connection with the Closing, BVF, BVF2, …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-20; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes